CDC - Testing Strategies for SARS-CoV-2 (includes Surveillance 12-28-2021) The CDC “Testing Strategies for SARS-CoV-2” guidance (updated Dec. 28, 2021) defines and contrasts diagnostic, screening, and public health surveillance testing, including intended use, who should be tested, and whether results can be returned to individuals. It states that diagnostic and screening testing require CLIA-certified testing sites and FDA-authorized (or FDA-policy) tests with individual and public health reporting requirements, while public health surveillance testing uses de-identified specimens, is not for individual decision-making, and does not require FDA/CLIA compliance. It includes a summary matrix comparing allowable settings, reporting, and result return across the three testing strategies. primary file regulatory surveillance CDC - Testing Strategies for SARS-CoV-2 (includes Surveillance 12-28-2021).md regulatory/surveillance/CDC - Testing Strategies for SARS-CoV-2 (includes Surveillance 12-28-2021).md 2021_12_08 pdf Public Domain 940 1412 gfile-url xfile-github-download-url pdf-gdrive-url pdf-github-url github-markdown-url github-markdown-download-url web-pdf-url web-slides-url youtube-url web-url